Literature DB >> 7308275

Pharmacokinetics and bioavailability of tranexamic acid.

A Pilbrant, M Schannong, J Vessman.   

Abstract

Tranexamic acid 1 g was given intravenously to three healthy volunteers. Plasma concentrations decayed in three monoexponential phases. Most elimination took place during the first eight hours, giving an apparent elimination half-life of approximately two hours. Plasma clearance ranged between 110-116 ml/min. The urinary recovery of tranexamic acid exceeded 95% of the dose. Ten healthy volunteers were given tranexamic acid 2 g orally on an empty stomach, and together with a meal. Food had no influence on the absorption of tranexamic acid, as judged by comparison of the peak plasma concentration, the time required to reach the peak, the AUC from zero to six hours, and the urinary excretion data. The oral bioavailability of tranexamic acid, calculated from 24 h urinary excretion after oral and intravenous administration, was 34% of the dose.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7308275     DOI: 10.1007/bf00554669

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Errors involved in instantaneous intravascular input assumptions.

Authors:  S Niazi
Journal:  J Pharm Sci       Date:  1976-05       Impact factor: 3.534

2.  Pharmacokinetics of tranexamic acid after intravenous administration to normal volunteers.

Authors:  O Eriksson; H Kjellman; A Pilbrant; M Schannong
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

3.  Statistical estimations in pharmacokinetics.

Authors:  H G Boxenbaum; S Riegelman; R M Elashoff
Journal:  J Pharmacokinet Biopharm       Date:  1974-04

4.  Tranexamic acid in upper gastrointestinal haemorrhage.

Authors:  F Cormack; R R Chakrabarti; A J Jouhar; G R Fearnley
Journal:  Lancet       Date:  1973-06-02       Impact factor: 79.321

5.  Antifibrinolytic therapy with Cyklokapron in connection with prostatectomy. A double blind study.

Authors:  P O Hedlund
Journal:  Scand J Urol Nephrol       Date:  1969

6.  Fibrinolysis and subarachnoid haemorrhage. Inhibitory effect of tranexamic acid. A clinical study.

Authors:  D Tovi; I M Nilsson; C A Thulin
Journal:  Acta Neurol Scand       Date:  1972       Impact factor: 3.209

7.  Problems associated with analysis of pharmacokinetic models.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

8.  Role of urokinase and tissue activator in sustaining bleeding and the management thereof with EACA and AMCA.

Authors:  L Andersson; I M Nilsoon; S Colleen; B Granstrand; B Melander
Journal:  Ann N Y Acad Sci       Date:  1968-06-28       Impact factor: 5.691

9.  Determination of tranexamic acid in biological material by electron capture gas chromatography after direct derivatization in an aqueous medium.

Authors:  J Vessman; S Strömberg
Journal:  Anal Chem       Date:  1977-03       Impact factor: 6.986

10.  Pharmacokinetic data. Pharmacokinetic parameters estimated from intravenous data by uniform methods and some of their uses.

Authors:  J G Wagner
Journal:  J Pharmacokinet Biopharm       Date:  1977-04
View more
  56 in total

1.  Design, synthesis and in vitro kinetic study of tranexamic acid prodrugs for the treatment of bleeding conditions.

Authors:  Rafik Karaman; Hiba Ghareeb; Khuloud Kamal Dajani; Laura Scrano; Hussein Hallak; Saleh Abu-Lafi; Gennaro Mecca; Sabino A Bufo
Journal:  J Comput Aided Mol Des       Date:  2013-07-24       Impact factor: 3.686

2.  Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.

Authors:  Swati Nagar; Richard C Korzekwa; Ken Korzekwa
Journal:  Mol Pharm       Date:  2017-07-31       Impact factor: 4.939

3.  Efficacy of combined use of intraarticular and intravenous tranexamic acid in total knee arthroplasty.

Authors:  Daniel R Whiting; Rafael J Sierra
Journal:  Ann Transl Med       Date:  2015-05

4.  Efficacy of Tranexamic Acid in Reducing Blood Loss during Maxillofacial Trauma Surgery-A Pilot Study.

Authors:  Abu Dakir; Balakrishnan Ramalingam; Vijay Ebenezer; Prakash Dhanavelu
Journal:  J Clin Diagn Res       Date:  2014-05-15

5.  The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury.

Authors:  Nikita Joshi; Anna K Kopec; Keara Towery; Kurt J Williams; James P Luyendyk
Journal:  J Pharmacol Exp Ther       Date:  2014-03-14       Impact factor: 4.030

6.  Preoperative Tranexamic Acid for Treatment of Bleeding, Edema, and Ecchymosis in Patients Undergoing Rhinoplasty: A Systematic Review and Meta-analysis.

Authors:  Sara Juliana de A de Vasconcellos; Edmundo M do Nascimento-Júnior; Marcel Vinícius de Aguiar Menezes; Mário Luis Tavares Mendes; Rafael de Souza Dantas; Paulo Ricardo Saquete Martins-Filho
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-09-01       Impact factor: 6.223

Review 7.  Interactions affecting drug absorption.

Authors:  P G Welling
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

8.  The ratio of concentrations of aminocaproic acid and tranexamic acid that prevent plasmin activation of platelets does not provide equivalent inhibition of plasmatic fibrinolysis.

Authors:  Vance G Nielsen; Paul M Ford
Journal:  J Thromb Thrombolysis       Date:  2018-10       Impact factor: 2.300

9.  Tranexamic acid reduces postoperative blood loss of degenerative lumbar instability with stenosis in posterior approach lumbar surgery: a randomized controlled trial.

Authors:  Qi Wang; Jun Liu; Rong Fan; Yu Chen; Hailong Yu; Yan Bi; Zhengzhe Hua; Meihui Piao; Mingming Guo; Weijian Ren; Liangbi Xiang
Journal:  Eur Spine J       Date:  2013-05-29       Impact factor: 3.134

10.  Population pharmacokinetics of tranexamic acid in paediatric patients undergoing craniosynostosis surgery.

Authors:  Susan M Goobie; Petra M Meier; Navil F Sethna; Sulpicio G Soriano; David Zurakowski; Snehal Samant; Luis M Pereira
Journal:  Clin Pharmacokinet       Date:  2013-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.